Nuo Therapeutics, Inc. (OTCQB: AURX) announced its financial results for the third quarter and first nine months of 2026. The company reported total revenues of approximately $1.9 million for the third quarter of 2026, a 123% increase compared to the same period in 2025. For the first nine months of 2026, total revenues reached approximately $4.9 million, representing a 123% increase over the first nine months of 2025.
Product sales for the third quarter of 2026 were $1,779,563, while distribution fee revenue was $86,562. The company noted that total product revenues increased 5% sequentially compared to the second quarter of 2026. Specifically, Aurix wound care revenues increased approximately 17% sequentially, maintaining the same average sequential growth rate observed over the past six quarters.
For the nine-month period, product sales totaled $4,694,782, and distribution fee revenue amounted to $242,444. The company reported a net operating loss of approximately $374,000 for the third quarter of 2026. This loss improved by approximately $166,000 compared to the third quarter of 2025 but increased by approximately $208,000 sequentially compared to the second quarter of 2026. The sequential increase was attributed to higher stock-based compensation, credit loss provisions, and regulatory costs exceeding $100,000 related to component supply matters.
In other operational updates, Nuo Therapeutics received a $250,000 reimbursement fee milestone pursuant to its 2025 distribution agreement with Smith+Nephew. Regarding Medicare reimbursement, the company noted that the final 2027 OPPS (Outpatient Prospective Payment System) ruling established a per treatment G0465 national average reimbursement of approximately $2,257, a 7% increase from 2026. Additionally, the Medicare PFS (Physician Fee Schedule) ruling set the G0465 national average reimbursement at approximately $1,020 for 2027, a decrease of approximately 4%.
Effective January 1, 2027, Medicare coverage and processing for G0465 claims in nursing home treatments (Place of Service 32) are set to expand. The company stated that this expansion is expected to be positive for future growth. Nuo Therapeutics also reported that subsequent to the quarter end, it received final funding of $325,000 under a loan agreement, bringing total borrowings to $2,000,000.